{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:27:02Z","timestamp":1792092422223,"version":"4.4.0"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T00:00:00Z","timestamp":1320192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Purpose:\u2002<\/jats:bold> To evaluate the long\u2010term efficacy and tolerability of adjunctive levetiracetam (LEV) in patients with uncontrolled idiopathic generalized epilepsy (IGE).<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> This phase III, open\u2010label, long\u2010term, follow\u2010up study (N167; NCT00150748) enrolled patients (4 to &lt;65\u2003years) with primary generalized seizures (tonic\u2013clonic, myoclonic, absence). Patients received adjunctive LEV at individualized doses (1,000\u20134,000\u2003mg\/day; 20\u201380\u2003mg\/kg\/day for children\/adolescents weighing &lt;50\u2003kg). Efficacy results are reported for all seizure types [intention\u2010to\u2010treat (ITT) population, N\u2003=\u2003217] and subpopulations with tonic\u2013clonic (n\u2003=\u2003152), myoclonic (n\u2003=\u2003121), and\/or absence (n\u2003=\u200370) seizures at baseline.<\/jats:p><jats:p><jats:bold>Key Findings:\u2002<\/jats:bold> One hundred twenty\u2010five (57.6%) of 217 patients were still receiving treatment at the end of the study. Mean (standard deviation, SD) LEV dose was 2,917.5 (562.9)\u2003mg\/day. Median (Q1\u2013Q3) exposure to LEV was 2.1 (1.5\u20132.8)\u2003years, and the maximum duration was 4.6\u2003years. Most patients were taking one (124\/217, 57.1%) or \u22652 (92\/217, 42.4%) concomitant antiepileptic drugs (AEDs). Seizure freedom of \u22656\u2003months (all seizure types; primary efficacy end point) was achieved by 122 (56.2%) of 217 patients, and 49 (22.6%) of 217 patients had complete seizure freedom. Seizure freedom of \u22656\u2003months from tonic\u2013clonic, myoclonic, and absence seizures was achieved by 95 (62.5%) of 152, 75 (62.0%) of 121, and 44 (62.9%) of 70 patients, respectively. Mean (SD) maximum seizure freedom duration was 371.7 (352.4)\u2003days. At least one treatment\u2010emergent adverse event (TEAE) was reported by 165 (76%) of 217 patients; most TEAEs were mild\/moderate in severity, with no indication of an increased incidence over time. Seventeen (7.8%) of 217 patients discontinued medication because of TEAEs. The most common psychiatric TEAEs were depression (16\/217, 7.4%), insomnia (9\/217, 4.1%), nervousness (8\/217, 3.7%), and anxiety (7\/217, 3.2%).<\/jats:p><jats:p><jats:bold>Significance:\u2002<\/jats:bold> Adjunctive LEV (range 1,000\u20134,000\u2003mg\/day) demonstrated efficacy as a long\u2010term treatment for primary generalized seizures in children, adolescents, and adults with IGE, and was well tolerated.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2011.03300.x","type":"journal-article","created":{"date-parts":[[2011,11,2]],"date-time":"2011-11-02T17:07:50Z","timestamp":1320253670000},"page":"111-119","source":"Crossref","is-referenced-by-count":41,"title":["Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open\u2010label, noncomparative, multicenter, long\u2010term follow\u2010up study"],"prefix":"10.1111","volume":"53","author":[{"given":"Norman","family":"Delanty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Tonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,11,2]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.09.003"},{"key":"e_1_2_7_3_1","first-page":"245","article-title":"UCB Pharma antiepileptic drug pregnancy registry","volume":"50","author":"Alekar S","year":"2009","journal-title":"Epilepsia"},{"key":"e_1_2_7_4_1","volume-title":"Survival analysis using SAS: a practical guide","author":"Allison PD","year":"1995"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163771.96962.1F"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00657.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00324.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000098891.76373.15"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.11.1757"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252941.50833.4a"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01278.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000174517.21383.36"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.26.15268"},{"key":"e_1_2_7_17_1","volume-title":"Analysis of clinical trials using SAS\u00ae: a practical guide","author":"Dmitrienko A","year":"2005"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.19704.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.8.1106"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000217916.00225.3a"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902014"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02129.x"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104123441504"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.00309.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.11.021"},{"key":"e_1_2_7_27_1","unstructured":"KennedyF MorrowJ HuntS RusselA SmithsonWH ParsonsL RobertsonI IrwinB DelantyN MorrisonPJ CraigJ. (2010)Malformation risks of antiepileptic drugs (AEDs) in pregnancy: an update from the UK epilepsy and pregnancy register. Oral presentation presented atEuropean Congress on Epileptology Rhodes."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/seiz.1999.0303"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02197.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.44.s.2.3.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2010.01.014"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0803531"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awq352"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02177.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000078031.32904.0D"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000297512.18364.40"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01981.x"},{"key":"e_1_2_7_40_1","first-page":"101","article-title":"Adjunctive levetiracetam in children aged 1\u2003month to <4\u2003years with partial\u2010onset seizures: a long\u2010term, multicenter, noncomparative, open\u2010label, follow\u2010up study","volume":"50","author":"Pi\u00f1a\u2010Garza JE","year":"2009","journal-title":"Epilepsia"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.02.016"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182088297"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.01.004"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"issue":"7","key":"e_1_2_7_45_1","first-page":"456","article-title":"Lack of seizure aggravation by levetiracetam in idiopathic generalized epilepsy: evidence from clinical trials","volume":"49","author":"Somerville ER","year":"2008","journal-title":"Epilepsia"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/35087000"},{"issue":"10","key":"e_1_2_7_47_1","first-page":"102","article-title":"Adjunctive levetiracetam in children and adolescents aged 4\u201316\u2003years with partial\u2010onset seizures: a long\u2010term, multicenter, non\u2010comparative, open\u2010label follow\u2010up study","volume":"50","author":"Yang H","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2011.03300.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2011.03300.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:55:34Z","timestamp":1697327734000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2011.03300.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1111\/j.1528-1167.2011.03300.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2011.03300.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,2]]}}}